177 related articles for article (PubMed ID: 27124898)
1. Modification of the HIV-specific CD8+ T-cell response in an HIV elite controller after chikungunya virus infection.
Ghiglione Y; Ruiz MJ; Salido J; Trifone C; Sued O; Martin Y; Patterson P; Laufer N; Turk G
AIDS; 2016 Jul; 30(12):1905-11. PubMed ID: 27124898
[TBL] [Abstract][Full Text] [Related]
2. Immune activation and antibody responses in non-progressing elite controller individuals infected with HIV-1.
Bello G; Velasco-de-Castro CA; Bongertz V; Rodrigues CA; Giacoia-Gripp CB; Pilotto JH; Grinsztejn B; Veloso VG; Morgado MG
J Med Virol; 2009 Oct; 81(10):1681-90. PubMed ID: 19697415
[TBL] [Abstract][Full Text] [Related]
3. Human immunodeficiency virus type 1-specific cytotoxic T lymphocyte activity is inversely correlated with HIV type 1 viral load in HIV type 1-infected long-term survivors.
Betts MR; Krowka JF; Kepler TB; Davidian M; Christopherson C; Kwok S; Louie L; Eron J; Sheppard H; Frelinger JA
AIDS Res Hum Retroviruses; 1999 Sep; 15(13):1219-28. PubMed ID: 10480635
[TBL] [Abstract][Full Text] [Related]
4. Immunoregulatory T cells may be involved in preserving CD4 T cell counts in HIV-infected long-term nonprogressors and controllers.
Gaardbo JC; Ronit A; Hartling HJ; Gjerdrum LM; Springborg K; Ralfkiær E; Thorsteinsson K; Ullum H; Andersen ÅB; Nielsen SD
J Acquir Immune Defic Syndr; 2014 Jan; 65(1):10-8. PubMed ID: 23995946
[TBL] [Abstract][Full Text] [Related]
5. HIV controllers with different viral load cutoff levels have distinct virologic and immunologic profiles.
Côrtes FH; Passaes CP; Bello G; Teixeira SL; Vorsatz C; Babic D; Sharkey M; Grinsztejn B; Veloso V; Stevenson M; Morgado MG
J Acquir Immune Defic Syndr; 2015 Apr; 68(4):377-385. PubMed ID: 25564106
[TBL] [Abstract][Full Text] [Related]
6. Elite controllers display higher activation on central memory CD8 T cells than HIV patients successfully on HAART.
López M; Soriano V; Peris-Pertusa A; Rallón N; Restrepo C; Benito JM
AIDS Res Hum Retroviruses; 2011 Feb; 27(2):157-65. PubMed ID: 20964478
[TBL] [Abstract][Full Text] [Related]
7. Adoptive lymphocyte transfer to an HIV-infected progressor from an elite controller.
Migueles SA; Chairez C; Lin S; Gavil NV; Rosenthal DM; Pooran M; Natarajan V; Rupert A; Dewar R; Rehman T; Sherman BT; Adelsberger J; Leitman SF; Stroncek D; Morse CG; Connors M; Lane HC; Kovacs JA
JCI Insight; 2019 Sep; 4(18):. PubMed ID: 31415245
[TBL] [Abstract][Full Text] [Related]
8. Rapid development of HIV elite control in a patient with acute infection.
Morley D; Lambert JS; Hogan LE; De Gascun C; Redmond N; Rutishauser RL; Thanh C; Gibson EA; Hobbs K; Bakkour S; Busch MP; Farrell J; McGetrick P; Henrich TJ
BMC Infect Dis; 2019 Sep; 19(1):815. PubMed ID: 31533639
[TBL] [Abstract][Full Text] [Related]
9. Transcriptional profiling of CD4 T cells identifies distinct subgroups of HIV-1 elite controllers.
Vigneault F; Woods M; Buzon MJ; Li C; Pereyra F; Crosby SD; Rychert J; Church G; Martinez-Picado J; Rosenberg ES; Telenti A; Yu XG; Lichterfeld M
J Virol; 2011 Mar; 85(6):3015-9. PubMed ID: 21177805
[TBL] [Abstract][Full Text] [Related]
10. Metabolic pathway activation distinguishes transcriptional signatures of CD8+ T cells from HIV-1 elite controllers.
Chowdhury FZ; Ouyang Z; Buzon M; Walker BD; Lichterfeld M; Yu XG
AIDS; 2018 Nov; 32(18):2669-2677. PubMed ID: 30289807
[TBL] [Abstract][Full Text] [Related]
11. The Breadth of Expandable Memory CD8+ T Cells Inversely Correlates with Residual Viral Loads in HIV Elite Controllers.
Ndhlovu ZM; Stampouloglou E; Cesa K; Mavrothalassitis O; Alvino DM; Li JZ; Wilton S; Karel D; Piechocka-Trocha A; Chen H; Pereyra F; Walker BD
J Virol; 2015 Nov; 89(21):10735-47. PubMed ID: 26269189
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of HIV-1 dual infection in long-term nonprogressor-elite controllers.
Pernas M; Casado C; Sandonis V; Arcones C; Rodríguez C; Ruiz-Mateos E; Ramírez de Arellano E; Rallón N; Del Val M; Grau E; López-Vazquez M; Leal M; Del Romero J; López Galíndez C
J Acquir Immune Defic Syndr; 2013 Nov; 64(3):225-31. PubMed ID: 23714744
[TBL] [Abstract][Full Text] [Related]
13. Kidney transplantation in an elite HIV controller: limited impact of immunosuppressive therapy on viro-immunological status.
Lambotte O; Lecuroux C; Saez-Cirion A; Barbet C; Shin SY; Boufassa F; Bastides F; Lebranchu Y
J Infect; 2012 Jun; 64(6):630-3. PubMed ID: 22406689
[No Abstract] [Full Text] [Related]
14. HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression.
Zaccarelli-Filho CA; Ono E; Machado DM; Brunialti M; Succi RC; Salomão R; Kallás EG; de Moraes-Pinto MI
Cytometry B Clin Cytom; 2007 Jan; 72(1):14-21. PubMed ID: 17041945
[TBL] [Abstract][Full Text] [Related]
15. Higher Frequency of NK and CD4+ T-Cells in Mucosa and Potent Cytotoxic Response in HIV Controllers.
Taborda NA; González SM; Alvarez CM; Correa LA; Montoya CJ; Rugeles MT
PLoS One; 2015; 10(8):e0136292. PubMed ID: 26291824
[TBL] [Abstract][Full Text] [Related]
16. Recovery of viremic control after superinfection with pathogenic HIV type 1 in a long-term elite controller of HIV type 1 infection.
Rachinger A; Navis M; van Assen S; Groeneveld PH; Schuitemaker H
Clin Infect Dis; 2008 Dec; 47(11):e86-9. PubMed ID: 18947331
[TBL] [Abstract][Full Text] [Related]
17. Rate and predictors of progression in elite and viremic HIV-1 controllers.
Leon A; Perez I; Ruiz-Mateos E; Benito JM; Leal M; Lopez-Galindez C; Rallon N; Alcami J; Lopez-Aldeguer J; Viciana P; Rodriguez C; Grau E; Iribarren J; Gatell JM; Garcia F;
AIDS; 2016 May; 30(8):1209-20. PubMed ID: 26854807
[TBL] [Abstract][Full Text] [Related]
18. In silico analysis of MHC-I restricted epitopes of Chikungunya virus proteins: Implication in understanding anti-CHIKV CD8(+) T cell response and advancement of epitope based immunotherapy for CHIKV infection.
Pratheek BM; Suryawanshi AR; Chattopadhyay S; Chattopadhyay S
Infect Genet Evol; 2015 Apr; 31():118-26. PubMed ID: 25643869
[TBL] [Abstract][Full Text] [Related]
19. Impact of hepatitis C virus coinfection on T-cell dynamics in long-term HIV-suppressors under combined antiretroviral therapy.
Zaegel-Faucher O; Bregigeon S; Cano CE; Obry-Roguet V; Nicolino-Brunet C; Tamalet C; Dignat-George F; Poizot-Martin I
AIDS; 2015 Jul; 29(12):1505-10. PubMed ID: 26244390
[TBL] [Abstract][Full Text] [Related]
20. Dynamics of cytomegalovirus (CMV)-specific T cells in HIV-1-infected individuals progressing to AIDS with CMV end-organ disease.
Bronke C; Palmer NM; Jansen CA; Westerlaken GH; Polstra AM; Reiss P; Bakker M; Miedema F; Tesselaar K; van Baarle D
J Infect Dis; 2005 Mar; 191(6):873-80. PubMed ID: 15717261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
